These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8459056)

  • 21. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
    Andersen K; Dellborg M
    Am J Cardiol; 1998 Apr; 81(8):939-44. PubMed ID: 9576150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction.
    Maruki Y; Onoda A; Matsuzaki M; Narabayashi Y; Sawada M; Shimazu K
    Keio J Med; 2000 Feb; 49 Suppl 1():A138-40. PubMed ID: 10750365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Argatroban.
    Am J Health Syst Pharm; 2001 Nov; 58(21):2027-9. PubMed ID: 11715823
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis.
    Kobayashi S; Tazaki Y
    Semin Thromb Hemost; 1997; 23(6):531-4. PubMed ID: 9469625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Argatroban use in dialysis patients.
    Reddy BV
    Semin Dial; 2004; 17(1):73. PubMed ID: 14717821
    [No Abstract]   [Full Text] [Related]  

  • 26. Low-molecular-weight heparins: an intriguing new twist with profound implications.
    Antman EM; Handin R
    Circulation; 1998 Jul; 98(4):287-9. PubMed ID: 9711931
    [No Abstract]   [Full Text] [Related]  

  • 27. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
    Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Argatroban therapy using enzymatic anti-factor IIa monitoring.
    Shepherd MF; Jacobsen JM; Rosborough TK
    Ann Pharmacother; 2011 Mar; 45(3):422-3. PubMed ID: 21386028
    [No Abstract]   [Full Text] [Related]  

  • 29. Coagulation laboratory testing in patients treated with argatroban.
    Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
    Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific antithrombins in the context of current treatment for acute coronary syndromes.
    Fox KA
    Eur Heart J; 1999 Nov; 20(21):1519-21. PubMed ID: 10529315
    [No Abstract]   [Full Text] [Related]  

  • 31. Argatroban approved for heparin-induced thrombocytopenia.
    Miller JL
    Am J Health Syst Pharm; 2000 Sep; 57(18):1650. PubMed ID: 11006790
    [No Abstract]   [Full Text] [Related]  

  • 32. Direct thrombin inhibitors in heparin-induced thrombocytopenia.
    Verme-Gibboney C; Dubb JW
    Am J Health Syst Pharm; 2005 Feb; 62(3):247-8; author reply 248, 250. PubMed ID: 15719581
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
    Mombelli G; Marchetti O; Haeberli A; Straub PW
    Am Heart J; 1998 Dec; 136(6):1106-13. PubMed ID: 9842027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease.
    Tomimoto H; Akiguchi I; Ohtani R; Yagi H; Ogura S; Wakita H
    Intern Med; 2000 Nov; 39(11):966-9. PubMed ID: 11065253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung].
    Tanaka K
    Fukuoka Igaku Zasshi; 2001 Jan; 92(1):7-20. PubMed ID: 11246985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
    Cella G; Girolami A; Sasahara AA
    Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacology of argatroban.
    Jeske WP; Fareed J; Hoppensteadt DA; Lewis B; Walenga JM
    Expert Rev Hematol; 2010 Oct; 3(5):527-39. PubMed ID: 21083469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
    Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Argatroban: for a few selected patients.
    Prescrire Int; 2013 Feb; 22(135):33-5. PubMed ID: 23444494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
    Lewis BE; Walenga JM; Wallis DE
    Semin Thromb Hemost; 1997; 23(2):197-202. PubMed ID: 9200347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.